Shockingly, the combined loss in market capitalization since late 2021 of Pfizer, Moderna, and BioNTech now exceeds the Gross Domestic Product (GDP) of Malaysia, South Africa, Denmark, the Philippines, Hong Song SAR, Columbia, Chile, the Czech Republic, Portugal, Finland, Greece, Hungary, Kuwait, Puerto Rico, Luxembourg, and most other countries. That […]
Pfizer’s Comirnaty mRNA COVID Vaccine Manufacturing Has Dropped by 89% Due to Decrease in Demand
The Follow the Money Team’s new report on Pfizer’s financials, based on Pfizer’s Q1 2023 reporting, offers many important insights: Pfizer reports that its mRNA COVID vaccine, Comirnaty®, manufacturing activities, performed on behalf of BioNTech, dropped 89% to only $5 million quarter-over-quarter. In its Q1 2023 report, Pfizer assumes no […]
Report 63: In Q3 2022, Pfizer Wrote Off $450 Million of Expired or Expiring COVID-19-Related Inventory.
Despite generating over $100 billion in revenue in 2022, Pfizer’s stock has dropped precipitously. Pfizer’s revenue was relatively flat, hovering between $41 billion and $51 billion, from 2014 to 2020. Then, its mRNA COVID-19 “vaccine” was awarded Emergency Use Authorization (EUA) by the Food and Drug Administration (FDA) on December […]